STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Genetic testing	$ 2,154,785	$ 2,757,355
Other	81,602	99,750
Total revenue	2,236,387	2,857,105
Cost of revenue	1,328,538	1,527,201
Gross profit	907,849	1,329,904
Operating expenses:
Research and development	1,311,877	1,376,394
Selling, general and administrative	4,150,607	4,665,360
Amortization of intangibles	115,453	115,453
Total operating expenses	5,577,937	6,157,207
Loss from operations	(4,670,088)	(4,827,303)
Other income (expense):
Interest income	4,485	6,419
Interest expense	(454,481)	(366,938)
Other income	0	4,274
Total other income (expense)	(449,996)	(356,245)
Loss from continuing operations before benefit for income taxes	(5,120,084)	(5,183,548)
Benefit for income taxes	0	0
Loss from continuing operations	(5,120,084)	(5,183,548)
Income from discontinued operations, net of tax	0	158,366
Net loss	$ (5,120,084)	$ (5,025,182)
Basic and diluted net loss per common share from:
Continuing operations	$ (0.14)	$ (0.14)
Discontinued operations	$ 0	$ 0.00
Net loss	$ (0.14)	$ (0.14)
Weighted average common shares outstanding, basic and diluted	36,754,679	36,661,290